Medtronic Leads $100 Million Strategic Investment in Pulnovo Medical

Pulnovo Medical has completed a 100 million dollar strategic financing round led by Medtronic, announced in a press release. Existing investors including EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures also participated, along with new investors such as HSG and other global funds.

Pulnovo and Medtronic have signed a commercial agreement that outlines potential future marketing opportunities. The collaboration aims to leverage Medtronic's global commercial capabilities alongside Pulnovo's technology.

Pulnovo develops a patented pulmonary artery denervation (PADN) system designed to address key mechanisms in cardiopulmonary diseases. The company has conducted about 1,500 PADN procedures worldwide and secured regulatory approvals in seven countries. It is expanding commercialization in the European Union, the Middle East, and China.

In the United States, Pulnovo has received the FDA Breakthrough Device designation and launched two fully approved Investigational Device Exemption trials led by Dr. Gregg Stone of Mount Sinai.